Net Asset Value

RNS Number : 0191H

Port Erin Biopharma Investments Ltd

05 July 2012

 



Port Erin Biopharma Investments Limited

("Port Erin" or "the Company")

Net Asset Value calculation for the third trading quarter to 30^th June 2012

Jim Mellon, Chairman, commented: -

"The Net Asset Value calculation for the Company as at closing on 30^th June 2012 was 9.46 pence per share, including un-invested cash of £237,391. The portfolio is valued at bid price. This represents a marginal decline from last quarter's valuation, but still maintains a satisfactory 14% gain on the initial net funds raised at inception."

		Unaudited 15 September 2011 to 30 June 2012 £
Fixed Assets
	Investments	2,892,182
Current Assets
	Debtors: amounts owing	9,511
	Uninvested cash	237,391
Current Liabilities
	Creditors: amounts due	(17,431)
		3,121,653
Capital and Reserves
	Share Capital	33
	Share Premium	3,000,967
	Capital reserve - realised	0
	Capital reserve - unrealised	0
	Revenue reserve	120,653
		3,121,653
Shares in Issue		33,000,000
Net Asset Value per share		9.46 pence
	Detailed Portfolio
Holding	£ Value @ 30/06/12	Portfolio %
Arrowhead Research Corp.	254,109	8.8%
Synergy Pharmaceuticals Inc.	242,293	8.4%
Plethora Solutions Holdings	241,045	8.3%
Pfizer Inc.	217,778	7.5%
Novartis AG	160,387	5.5%
Gilead Sciences Inc.	141,167	4.9%
Astellas Pharmaceuticals Inc.	140,607	4.9%
Summit Corporation plc	128,055	4.4%
Abbott Laboratories	119,680	4.1%
Merck & Co. Inc.	101,564	3.5%
Nektar Therapeutics	86,706	3.0%
Immunocellular Therapeutics Ltd.	85,760	3.0%
H. Lundebeck A/S	73,848	2.6%
Rigel Pharmaceuticals	72,652	2.5%
Onyx Pharmaceuticals	68,069	2.4%
Medivation Inc.	64,372	2.2%
Map Pharmaceuticals Inc.	64,138	2.2%
Medivir AB-B	63,169	2.2%
Celgene Corp.	57,508	2.0%
Shire plc	55,139	1.9%
Siga Technologies Inc.	42,121	1.5%
Thershold Pharmaceuticals, Inc.	41,406	1.4%
Synta Pharmaceuticals Inc.	40,556	1.4%
Pharmathene Inc.	37,283	1.3%
Keryx Biopharmaceuticals Inc.	34,578	1.2%
Miraculins Inc.	30,057	1.0%
Biotime Inc.	27,628	1.0%
Orexigen Therapeutics, Inc.	26,510	0.9%
Methylgene Inc.	19,648	0.7%
Pacific Biosciences California Inc.	17,460	0.6%
Complete Genomics Inc.	16,079	0.6%
Polymedix Inc.	14,215	0.5%
Synergy - warrants (publicly traded)	10,547	0.4%
Loan: Ampliphi Biosciences Corp.	64,033	2.2%
Loan: Spiritus Pharmaceuticals, LLC	32,016	1.1%
	2,892,182	100.0%

ENDS  

For further information, please contact:

Port Erin Biopharma Investments Ltd	Libertas Capital Corporate Finance Limited	Rivington Street Corporate Finance Limited
The Company	Nomad	Broker
Denham Eke [phone]	Sandy Jamieson [phone]	Jon Levinson [phone]

 

END

 

 

NAVLLFIFDDIEIIF